Avadel Pharmaceuticals (AVDL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Avadel Pharmaceuticals (AVDL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

8.03

0.21 (2.69%)

At close: Jan 14, 2025, 3:59 PM

8.37

4.30%

After-hours Jan 14, 2025, 07:55 PM EST

undefined% (undefined)

Bid	8.3
Market Cap	773.30M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.75
PE Ratio (ttm)	-10.7
Forward PE	n/a
Analyst	Buy

Ask	8.45
Volume	1,509,306
Avg. Volume (20D)	1,403,250
Open	7.87
Previous Close	7.82
Day's Range	7.78 - 8.34
52-Week Range	7.39 - 19.09
Beta	undefined

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorpo...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jun 7, 1996

Employees 154

Stock Exchange NASDAQ

Ticker Symbol AVDL

Website https://www.avadel.com

Analyst Forecast

According to 6 analyst ratings, the average rating for AVDL stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 149.22% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Avadel Pharmaceuticals is scheduled to release its earnings on Mar 3, 2025, before market opens.
Analysts project revenue of $52.70M, reflecting a 170.91% YoY growth and earnings per share of -0.04, making a -87.50% decrease YoY.

Why Price Moved

6 days ago · Source

-1.57%

Avadel Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription

2 months ago · Source

-8.59%

Avadel Pharmaceuticals shares are trading lower after HC Wainwright maintained a Buy rating on the stock and cut its price target from $27 to $25.

News

1 day ago · seekingalpha.com

3 Oversold Biotech Names

High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...

3 days ago · seekingalpha.com

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Avadel Pharmaceuticals' 2025 net sales guidance for Lumryz was significantly below expectations due to increasing patient attrition. The company is increasing efforts to address some of these challeng...

2 months ago · seekingalpha.com

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - CEO Richard Kim - CCO ...

2 months ago · zacks.com

Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.

2 months ago · reuters.com

US FDA expands approval for Avadel's sleep disorder drug

The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for widely used treatm...